KZIA

Kazia TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$19.00

+61.2% vs current

Most likely

Base case

45%

Probability

Target price

$12.00

+1.8% vs current

B-

Bear case

30%

Probability

Target price

$5.50

-53.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-28

AI commentary

Recent disclosed newsflow is directionally positive but mostly company-controlled: January's preliminary TNBC response update, March's catalyst map and runway framing, and April's SETDB1 platform expansion. The packet contains no recent trusted-news coverage and no usable social-coverage readout, so sentiment should be treated as event-driven and low-conviction rather than broadly validated by third-party follow-through.

RankAlpha Sentiment Codex - 2026-04-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventFDA path-forward update for paxalisib in glioblastomaHigh impact

Kazia's March 2026 investor fact sheet lists a Q2 2026 update from FDA discussions on paxalisib's commercial and development path forward in GBM; for a low-coverage biotech, any clarity on registrational strategy or trial design could materially reset expectations, but the event is still guidance-level until disclosed [#IR-2026-03-27].

2026-09-30event2H 2026 neuro-oncology readouts in GBM and brain metastasesHigh impact

Kazia flagged 2H 2026 readouts from neuro-oncology-focused clinical trials in patients with GBM and brain metastases, which are the most decision-relevant proof points for paxalisib beyond narrative platform expansion [#IR-2026-03-27].

2026-09-30catalystPipeline expansion beyond paxalisib may broaden strategic optionalityHigh impact

Kazia added a first-in-class SETDB1-targeted platform in April 2026 and separately guided to Q2 2026 advancement of NDL2 toward IND-enabling studies; these programs can improve partnering narrative, but they are earlier-stage than paxalisib and should not yet be treated as near-term value anchors [#PR-2026-04-13] [#IR-2026-03-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-28 • Updated nightlySource: Internal modelMethodology